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Inflammation, Thrombosis and Vascular Biology: Translating Ideas into Cardiovascular Research and Therapy 
Advances in basic and clinical sciences over the past decades have substantially improved our understanding of inflammatory 
and thrombotic pathways implicated in atherogenesis. It is now clear that multiple genetic and environmental factors interfere 
with the natural course of atherosclerosis in early life and lead toward premature clinical manifestations in the adolescence and 
in the middle age. Importantly, various molecular and cellular agents with pro-atherogenic properties have been identified, and 
similarities have been found between atherosclerotic vascular disease, chronic inflammatory disorders and cancer [1, 2], all of 
which can be viewed as diseases of premature aging. Identification of common pathways of aging, and premature morbidity 
and mortality in these disorders has prompted the search for therapeutic means with universal beneficial effects. In fact, over 
the past decade, we have witnessed a strong emphasis on anti-inflammatory effects of cardiovascular drugs, such as angiotensin 
converting enzyme inhibitors (ACE-I), statins, aspirin, which are believed to reduce incidence of vascular events by acting not 
only on their primary therapeutic targets but also on the inflammatory process [3]. 
The first report on predictive vascular value of levels of C-reactive protein (CRP) [4] revolutionized cardiovascular research, 
and directed efforts of cardiologists and allied professionals toward elaboration of a new cardiovascular preventive strategy 
based on the current view on atherosclerosis as an inflammatory disorder. 
Preventive measures against established cardiovascular risk factors (e.g., dyslipidemia, hypertension, active and passive 
smoking, obesity) proved efficient in reducing inflammatory burden in the general population and in patients with established 
cardiovascular disease, and it seems obvious that simple non-medicamentous preventive measures started early in life may 
substantially reduce incidence of cardiovascular events and contribute to healthy aging [5]. 
As more data on genetic polymorphisms underlying inflammation have accumulated [6], it has become possible to outline 
directions of cardiovascular prevention, which should take into account variability of expression of major mediators of systemic 
inflammation (e.g., CRP, pro-inflammatory cytokines). Whether the screening for genetic polymorphisms of CRP and other 
mediators should be part of community-based cardiovascular preventive measures is still not clear. Added to the complexity, 
the number of inflammatory mediators of atherogenesis is constantly increasing [7], and it is still poorly understood how 
genetic polymorphisms of so many ‘major’ and ‘minor’ contributors to atherogenesis interact with each other and form basis 
for accelerated atherosclerosis. Perhaps future basic research on animal models of atherosclerosis with knock-out inflammatory 
genes will provide more specific answers. In fact, the latter experimental approach proved useful in understanding a variety  
of molecular mechanisms implicated in hypertension, atherosclerosis and other cardiovascular and hematological disorders  
[8]. 
An important factor, which is closely but not exclusively related to the genetic predisposition to accelerated atherosclerosis, is 
ethnicity. It is well known that the majority of recent large trials on cardiovascular disease prevention and treatment are based 
on cohorts of subjects from Western countries, mainly Caucasians. However, ethnic origin, geographic location, level of 
education, social, religious, and cultural factors may substantially influence the course of cardiovascular disease. Over the past 
few years, importance of these factors has been appreciated in a few well-designed studies comparing cardiovascular risk 
factors in cohorts of subjects from the Eastern and Western countries [9]. Researchers’ interest toward an excess of 
cardiovascular morbidity and mortality among South Asians is growing in the UK [10] and the US [11]. Recently, several new 
markers of increased cardiovascular risk in South Asians have been proposed, with dysfunctional high density lipoproteins and 
high sensitivity CRP being widely studied [12]. Importantly, the loss of anti-inflammatory properties of HDL was associated 
with an increased atherosclerotic burden in South Asians [13]. The obtained data indicate the need for large scale prospective 
studies, which will allow elaborating ethnic specific cardiovascular prevention guidelines [14]. 
The concept of atherosclerosis as an inflammatory disorder has been substantially enriched due to large cohort studies on 
enhanced atherosclerotic cardiovascular disease in high-grade inflammatory disorders such as systemic lupus erythematosus 
(SLE) and rheumatoid arthritis (RA) [15, 16]. Both diseases are now viewed as clinical models of inflammation-induced 
atherogenesis. Anti-rheumatic drugs used in these disorders are believed to suppress intensity of inflammatory and pro-
thrombotic pathways of atherogenesis and, thus, to prevent vascular events. Specifically designed prospective studies to prove 
this hypothesis are warranted. One of the relatively safe anti-rheumatic drugs, methotrexate, has been already suggested for the 
suppression of overproduction of CRP and prevention of cardiovascular events in the general population [17]. It is expected 
that elaboration of other clinical models of atherogenesis, particularly those associated with low-grade systemic inflammation, 
will further expand the armamentarium of potent anti-inflammatory drugs useful in cardiovascular disease states [18]. A few 
recent studies on non-rheumatic cardiovascular disease have already outlined relatively safe anti-inflammatory profile of 
colchicine, which was initially demonstrated its efficiency in familial Mediterranean fever (FMF), an emerging clinical model 
of atherosclerosis associated with low-grade inflammation [19]. 
Interestingly, not all systemic inflammatory disorders predispose to accelerated atherogenesis. Wegener’s granulomatosis (WG) 
[20], Behçet’s disease (BD) [21], and some other vasculitides are good examples of clinical course of chronic inflammation, 
damaging the endothelium, and leading to vascular aneurysms, arterial and venous thrombosis but not to atherosclerotic Editorial  The Open Cardiovascular Medicine Journal, 2010, Volume 4    21 
vascular disease. Mechanisms of this vasculitic damage, shifting inflammatory burden toward pro-thrombotic state, are not 
fully understood. Perhaps future large studies on genetic polymorphisms responsible for overexpession of thrombogenic factors 
in BD and other vasculitides will partially explain this phenomenon [22]. 
It is also worth noting that specifically designed comparative studies on cardiovascular manifestations and atherogenesis in 
different low- (FMF, BD) and high-grade inflammatory disorders (RA, SLE) will make it possible to better understand 
atherogenic and pro-thrombotic implications of inflammation, and to provide the clinician with recommendations for 
antithrombotic therapy. Unfortunately, currently available guidelines on antithrombotic therapy do not provide answers to the 
questions of how and when to treat patients with inflammatory disorders at high atherothrombotic risk. To some extent, it is due 
to high risk of bleeding conferred by anti-platelet and anti-coagulant therapies in chronic inflammatory disorders, and due to 
exclusion of patients with these disorders from the major trials. Of note, patients with BD, who frequently present with 
pulmonary aneurysms, are at high risk of pulmonary hemorrhage, which may further increase in the case of anticoagulation. 
These and related issues of antithrombotic therapy are comprehensively covered in some reviews of this issue [22, 23]. 
Intensity of inflammation is a crucial pathophysiological factor, which should be viewed as a target of current anti-rheumatic 
and anti-thrombotic therapies. However, each inflammatory disorder has its specific targets, which specifically contribute to 
vascular pathology (e.g., neutrophilic aggression in FMF, BD, WG, autoantibodies in SLE and RA). In each of these disorders, 
vasculopathy is established in numerous observational studies with healthy controls [24]. What is more interesting and useful is 
to compare the contribution of these specific factors on vasculopathy in comparative studies with appropriately matched 
inflammatory disease controls. 
Therapeutic targets in inflammatory disorders widely vary. In RA, for example, physical inactivity can be viewed as a specific 
target. Enhanced physical activity is thought to decrease inflammatory burden and ameliorate endothelial function in this 
disorder [25]. Mechanisms of endothelial dysfunction in RA and targeted action of physical activity on inflammatory changes 
in the endothelium are analyzed in this issue [25]. It is hoped that future studies of the effects of physical activity on 
endothelial, inflammatory and pro-thrombotic agents in RA will have practical implications for patients with inflammatory 
polyarthritis and non-RA subjects with sedentary lifestyle. 
Finally, over the past decade, substantial achievements were made in the field of stem cell research and therapy. It was shown 
that chronic inflammation interferes with the process of endothelial regeneration and, thereby, contributes to endothelial 
dysfunction [26]. Attempts were made to use bone marrow derived stem cells for therapeutic purposes in several cardiovascular 
disorders [27]. Whether this approach will be also useful in chronic inflammatory disorders is not clear. Perhaps the most 
important limiting factor, in this regard, is the difficulty to isolate stem/progenitor cells with the required cardiovascular or 
endothelial differentiation properties [28]. 
Selected reviews presented in this issue summarize available data on inflammation-induced atherosclerosis, thrombosis and 
vascular biology. In some of these reviews, special attention is paid to the ongoing attempts to elaborate clinical models of 
accelerated atherosclerosis associated with low- and high-grade inflammatory disorders, which shed light into the targets for 
future cardiovascular preventive measures. It is evident that multiple genetic and environmental factors underlie activation of 
pro-atherogenic molecular and cellular agents. Atherosclerosis shares pathophysiological features with a variety of chronic 
inflammatory disorders and cancer, and better understanding of vasculopathy in each of these conditions will boost research 
studies for years to come, and will lead to practical recommendations for healthy subjects and patients with established 
cardiovascular disease. 
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